Table 2.
Distribution and statistical comparison of HPV18 lineages between the AA and E lineages
| AA(n = 89) | E(n = 8) | P value | ||
|---|---|---|---|---|
| Age, years | 46 (40–54) | 58 (47–63) | 0.344* | |
| Cervical lesion, n | Grouping | |||
| Normal | ① | 22 (24.7%) | 3 (37.5%) | 0.298† |
| ASCUS | ② | 5 (5.6%) | 2 (25.0%) | |
| LSIL/CIN1 | ③ | 34 (38.2%) | 1 (12.5%) | |
| HSIL/CIN2&3 | ④ | 17 (19.1%) | 1 (12.5%) | |
| Cancer | ⑤ | 11 (12.4%) | 1 (12.5%) | |
| Pathology and treatment, n | ||||
| Cancer | ⑤ | 11 (12.4%) | 1 (12.5%) | 1.000‡ |
| Non-cancer | ① + ② + ③ + ④ | 78 (87.6%) | 7 (87.5%) | |
| Surgery | ④ + ⑤ | 28 (31.5%) | 2 (25.0%) | 1.000‡ |
| Observation | ① + ② + ③ | 61 (68.5%) | 6 (75.0%) | |
| Definite dysplasia | ③ + ④ + ⑤ | 62 (69.7%) | 3 (37.5%) | 0.110‡ |
| Normal and ASCUS | ① + ② | 27 (30.3%) | 5 (62.5%) | |
| Evidence of co-infection, n | ||||
| With other risk type(s) | 21 (23.6%) | 2 (25.0%) | 1.000‡ | |
| With other high-risk type(s) | 16 (18.0%) | 1 (12.5%) | 1.000‡ | |
| §Serial follow-up testing (n = 54) | ||||
| Progression (n) | n = 50 | n = 4 | ||
| Progression | 21 (42.0%) | 1 (25.0%) | 0.773‡ | |
| No progression | 29 (58.0%) | 3 (75.0%) | ||
* Mann-Whitney test
† Linear by linear association
‡ Fisher’s exact test
§ 54 out of 97 patients underwent serial pathological examinations
Grouping: ① Normal, ② ASCUS, ③ LSIL/CIN1, ④ HSIL/CIN2 and 3, ⑤ Cancer
Abbreviation: AA Asian-Amerindian; E European; ASCUS Atypical squamous cells of undetermined significance; LSIL Low-grade squamous intraepithelial lesion; HSIL High-grade squamous intraepithelial lesion; CIN Cervical intraepithelial neoplasia